ConductScience.org, home

Paper36214865

Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.

Tuli HS and 12 others. Naunyn Schmiedebergs Arch Pharmacol, 2023. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives. Papers, record 36214865. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36214865

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.
PubMed
Journal
Naunyn Schmiedebergs Arch Pharmacol
PubMed
Year
2023
PubMed
Publication types
Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
1.69
iCite
Revised in PubMed
2026-10-30
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tuli HSHardeep Singh
2Garg VKVivek Kumar
3Kumar AAjay
4Aggarwal DDiwakar
5Anand UUttpal
6Parashar NCNidarshana Chaturvedi
7Saini AKAdesh K
8Mohapatra RKRanjan K
9Dhama KKuldeep
10Kumar MManoj
11Singh TTejveer
12Kaur JJagjit
13Sak KKatrin

Source PubMed

Download CSV of authors

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
FlavonoidsMajor topic
Antineoplastic AgentsMajor topic
Signal Transduction
Cell Line, Tumor

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in38619590Correction: Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.https://conductscience.org/library/papers/38619590

Source PubMed

Download CSV of comments and corrections

References136

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116321545A review on pro- and anti-angiogenic factors as targets of clinical intervention.Pharmacol Res2006https://conductscience.org/library/papers/16321545PubMed
235480139Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures.Biomed Res Int2022https://conductscience.org/library/papers/35480139PubMed
324634660Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis.Front Physiol2014https://conductscience.org/library/papers/24634660PubMed
415036470Cytotoxic activities of flavonoids from two Scutellaria plants in Chinese medicine.J Ethnopharmacol2004https://conductscience.org/library/papers/15036470PubMed
522155252A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo.Biochem Biophys Res Commun2012https://conductscience.org/library/papers/22155252PubMed
625304218Natural product inhibitors of ocular angiogenesis.Exp Eye Res2014https://conductscience.org/library/papers/25304218PubMed
731402703An unambiguous and practical synthesis of Oroxylin A: a commonly misidentified flavone.Nat Prod Res2021https://conductscience.org/library/papers/31402703PubMed
88701285Fighting cancer by attacking its blood supply.Sci Am1996https://conductscience.org/library/papers/8701285PubMed
928938606Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome.Oncotarget2017https://conductscience.org/library/papers/28938606PubMed
1020411407Use of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin A by human liver and intestinal microsomes.Pharm Res2010https://conductscience.org/library/papers/20411407PubMed
1128726775Oroxylin A activates PKM1/HNF4 alpha to induce hepatoma differentiation and block cancer progression.Cell Death Dis2017https://conductscience.org/library/papers/28726775PubMed
1219626645Involvement of p53 in oroxylin A-induced apoptosis in cancer cells.Mol Carcinog2009https://conductscience.org/library/papers/19626645PubMed
1334117368Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression.Acta Pharmacol Sin2022https://conductscience.org/library/papers/34117368PubMed
1434656666Ethnodermatological use of medicinal plants in India: From ayurvedic formulations to clinical perspectives - A review.J Ethnopharmacol2022https://conductscience.org/library/papers/34656666PubMed
1530318784Oroxylin A inhibits Kaposi's sarcoma-associated herpes virus (KSHV) vIL-6-mediated lymphatic reprogramming of vascular endothelial cells through modulating PPARγ/Prox1 axis.J Med Virol2019https://conductscience.org/library/papers/30318784PubMed
1625218897Oroxylin A enhances memory consolidation through the brain-derived neurotrophic factor in mice.Brain Res Bull2014https://conductscience.org/library/papers/25218897PubMed
1723934681Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα.Int J Cancer2014https://conductscience.org/library/papers/23934681PubMed
1831927013Pharmacokinetics, tissue distribution and excretion study of Oroxylin A, Oroxylin A 7-O-glucuronide and Oroxylin A sodium sulfonate in rats after administration of Oroxylin A.Fitoterapia2020https://conductscience.org/library/papers/31927013PubMed
1932999161Oroxylin A Exerts Its Antitumor Effects in Human Gallbladder Cancer via Inhibition of the PTEN/PI3K/AKT Signaling Pathway.Biol Pharm Bull2020https://conductscience.org/library/papers/32999161PubMed
2018828708Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment.Antioxid Redox Signal2009https://conductscience.org/library/papers/18828708PubMed

See all 136 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
41049034Deciphering the Role of Oroxylin A in Liver Fibrosis.Drug Des Devel Ther2025https://conductscience.org/library/papers/41049034PubMed
41032091Oroxylin A exerts antiproliferative effects through downregulation of E6 and E7 oncogenes in cervical cancer HeLa cells.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/41032091PubMed
40211010Oroxylin A may promote cell apoptosis and inhibit epithelial-mesenchymal transition in endometrial cancer, associated with the ERβ/PI3K/AKT pathway.Sci Rep2025https://conductscience.org/library/papers/40211010PubMed
39834817An updated review summarizing the anticancer potential of flavonoids via targeting NF-kB pathway.Front Pharmacol2024https://conductscience.org/library/papers/39834817PubMed
39804528Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.Mol Neurobiol2025https://conductscience.org/library/papers/39804528PubMed
38730663The Role of Phytonutrient Kaempferol in the Prevention of Gastrointestinal Cancers: Recent Trends and Future Perspectives.Cancers (Basel)2024https://conductscience.org/library/papers/38730663PubMed
36840363Nano-biotechnology in tumour and cancerous disease: A perspective review.J Cell Mol Med2023https://conductscience.org/library/papers/36840363PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36214865

GET https://conductscience.org/api/papers/v1/36214865/references?page=2